9 Recruiting Chronic Myelomonocytic Leukemia Phase 2 Clinical Trials
Active phase 2 studies for chronic myelomonocytic leukemia enrolling across the USA. Verify eligibility and contact site coordinators.
All Chronic Myelomonocytic Leukemia studiesPhase 2 Studies for Chronic Myelomonocytic Leukemia
🔵 Active, Not Recruiting Phase2
Azacitidine With or Without Lenalidomide or Vorinostat in Treating Patients With Higher-Risk Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia
📍 University of Alabama at Birmingham Cancer Center — Birmingham, Alabama
View Study & Checklist ➔ 🔵 Active, Not Recruiting Phase2
Ruxolitinib for the Treatment of Chronic Myelomonocytic Leukemia (CMML): A Phase 2 Expansion
📍 H. Lee Moffitt Cancer Center and Research Institute — Tampa, Florida
View Study & Checklist ➔ 🔵 Active, Not Recruiting Phase1 / Phase2
Phase I/II Study of Tagraxofusp in Combination With Decitabine for Patients With Myelomonocytic/Myeloproliferative Neoplasm and High Risk Myelodysplastic Syndromes
📍 M D Anderson Cancer Center — Houston, Texas
View Study & Checklist ➔ 🔵 Active, Not Recruiting Phase1 / Phase2
Venetoclax in Combination With ASTX727 for the Treatment of Treatment-Naive High-Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia
📍 M D Anderson Cancer Center — Houston, Texas
View Study & Checklist ➔ 🔵 Active, Not Recruiting Phase1 / Phase2
Guadecitabine and Atezolizumab in Treating Patients With Advanced Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia That Is Refractory or Relapsed
📍 USC / Norris Comprehensive Cancer Center — Los Angeles, California
View Study & Checklist ➔ 🔵 Active, Not Recruiting Phase2
Venetoclax in Combination With ASTX727 for the Treatment of Chronic Myelomonocytic Leukemia and Other Myelodysplastic Syndrome/Myeloproliferative Neoplasm
📍 Mayo Clinic Hospital in Arizona — Phoenix, Arizona
View Study & Checklist ➔ 🔵 Active, Not Recruiting Phase1 / Phase2
Azacitidine and Quizartinib for the Treatment of Myelodysplastic Syndrome or Myelodysplastic/Myeloproliferative Neoplasm With FLT3 or CBL Mutations
📍 MD Anderson Cancer Center — Houston, Texas
View Study & Checklist ➔ 🟢 Recruiting Phase1 / Phase2
Pacritinib in CMML
📍 The Mount Sinai Hospital — New York, New York
View Study & Checklist ➔ 🟢 Recruiting Phase2
A Phase II, Open-Label, Study of Subcutaneous Canakinumab, an Anti-IL-1β Human Monoclonal Antibody, for Patients With Low or Int-1 Risk IPSS/IPSS-R Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia
📍 M D Anderson Cancer Center — Houston, Texas
View Study & Checklist ➔